Oncology

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

News

FDA clears Gamida’s cord blood therapy for cancer patients

The FDA has approved a stem cell-based therapy for cancer patients from Israeli biotech Gamida Cell that is designed to help them recover more quickly from aggressive chem

R&D

Restoring sensitivity to targeted therapies

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Steven Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialis

News

Scheme aims to boost equity in digital cancer resources

Telehealth company Equiva has started working with cancer charity Gilda’s Club to make it easier for households affected by cancer in Minnesota to access online support re

News

More claudin buzz as Alentis raises $105m

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d

Oncology

12 Questions with David Long

David Long leads the Oncology Business Unit at MSD in the UK and brings a wealth of experience from his 20 years within the organisation, having held a variety of local, regional and global

BMS goes down the Tubulis route for cancer ADCs

FDA clears Gamida’s cord blood therapy for cancer patients

Restoring sensitivity to targeted therapies

Scheme aims to boost equity in digital cancer resources

More claudin buzz as Alentis raises $105m

12 Questions with David Long

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks